115 related articles for article (PubMed ID: 17555397)
1. Second-line therapy for esophageal cancer.
Martin MG; Govindan R; Morgensztern D
Expert Rev Anticancer Ther; 2007 Jun; 7(6):871-6. PubMed ID: 17555397
[TBL] [Abstract][Full Text] [Related]
2. Palliative chemotherapy for recurrent and metastatic esophageal cancer.
Grünberger B; Raderer M; Schmidinger M; Hejna M
Anticancer Res; 2007; 27(4C):2705-14. PubMed ID: 17695436
[TBL] [Abstract][Full Text] [Related]
3. [Chemotherapy after second-line chemotherapy for patients with advanced or metastatic breast cancer].
Ogasawara Y; Doihara H; Takahashi M; Kawasaki K; Taira N
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1713-6. PubMed ID: 18931574
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced esophageal cancer.
Kelsen D
Cancer; 1982 Dec; 50(11 Suppl):2576-81. PubMed ID: 6182976
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment for oesophageal cancer.
van Meerten E; van der Gaast A
Eur J Cancer; 2005 Mar; 41(5):664-72. PubMed ID: 15763640
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of chemotherapy and chemo-radiotherapy in patients with metastatic esophageal cancer].
Mitsuhashi T; Miyazaki T; Sakimoto T; Kubo N; Ishiguro T; Okada N; Yokoyama M; Ishibashi K; Matsuki M; Takahashi T; Ishida H
Gan To Kagaku Ryoho; 2008 Nov; 35(12):1999-2001. PubMed ID: 19106503
[TBL] [Abstract][Full Text] [Related]
7. Second-line therapy in bladder cancer.
Bachner M; De Santis M
Curr Opin Urol; 2009 Sep; 19(5):533-9. PubMed ID: 19550334
[TBL] [Abstract][Full Text] [Related]
8. Esophageal cancer: a critical evaluation of systemic second-line therapy.
Thallinger CM; Raderer M; Hejna M
J Clin Oncol; 2011 Dec; 29(35):4709-14. PubMed ID: 22067408
[TBL] [Abstract][Full Text] [Related]
9. The role of salvage treatment in advanced colorectal cancer.
Capdevila J; Ramos FJ; Macarulla T; Elez E; Tabernero J
Crit Rev Oncol Hematol; 2009 Jul; 71(1):53-61. PubMed ID: 18977669
[TBL] [Abstract][Full Text] [Related]
10. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
Gallagher DJ; Milowsky MI; Bajorin DF
Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
[TBL] [Abstract][Full Text] [Related]
11. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
Garmey EG; Sartor O; Halabi S; Vogelzang NJ
Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
[TBL] [Abstract][Full Text] [Related]
12. Intermittent therapy in the palliative treatment of metastatic colorectal cancer.
Wadhawan A; Stephens R; Adams R
Expert Rev Anticancer Ther; 2009 Jan; 9(1):125-34. PubMed ID: 19105712
[TBL] [Abstract][Full Text] [Related]
13. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.
Crumley AB; Stuart RC; McKernan M; McDonald AC; McMillan DC
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e325-9. PubMed ID: 17645468
[TBL] [Abstract][Full Text] [Related]
14. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma.
Tachimori Y; Kanamori N; Uemura N; Hokamura N; Igaki H; Kato H
J Thorac Cardiovasc Surg; 2009 Jan; 137(1):49-54. PubMed ID: 19154902
[TBL] [Abstract][Full Text] [Related]
15. [The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO)].
Yokoyama T; Tokuhara H; Egawa T; Hashimoto O; Seki H; Koyanagi K; Bessho T
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1667-70. PubMed ID: 19838025
[TBL] [Abstract][Full Text] [Related]
16. Esophageal cancer: current and emerging therapy modalities.
Ekman S; Dreilich M; Lennartsson J; Wallner B; Brattström D; Sundbom M; Bergqvist M
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1433-48. PubMed ID: 18759695
[TBL] [Abstract][Full Text] [Related]
17. Review of second-line chemotherapy for advanced gastric adenocarcinoma.
Wilson D; Hiller L; Geh JI
Clin Oncol (R Coll Radiol); 2005 Apr; 17(2):81-90. PubMed ID: 15830569
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategy for treatment of metastatic non-small cell lung cancer.
Berhoune M; Banu E; Scotte F; Prognon P; Oudard S; Bonan B
Ann Pharmacother; 2008 Nov; 42(11):1640-52. PubMed ID: 18957625
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus.
Ariga H; Nemoto K; Miyazaki S; Yoshioka T; Ogawa Y; Sakayauchi T; Jingu K; Miyata G; Onodera K; Ichikawa H; Kamei T; Kato S; Ishioka C; Satomi S; Yamada S
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):348-56. PubMed ID: 19735862
[TBL] [Abstract][Full Text] [Related]
20. Maintenance treatment in metastatic breast cancer.
Sánchez-Muñoz A; Pérez-Ruiz E; Ribelles N; Márquez A; Alba E
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1907-12. PubMed ID: 19046111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
